A mutation in the DNA-binding domain of the androgen receptor gene causes complete testicular feminization in a patient with receptor-positive androgen resistance.

Marco Marcelli, S. Zoppi, Placido B. Grino, Jim E. Griffin, Jean D. Wilson, Michael J. McPhaulJournal of Clinical Investigation 1991 · DOI

Abstract

Androgen resistance is associated with a wide range of quantitative and qualitative defects in the androgen receptor. However, fibroblast cultures from approximately 10% of patients with the clinical, endocrine, and genetic features characteristic of androgen resistance express normal quantities of apparently normal androgen receptor in cultured genital skin fibroblasts (receptor-positive androgen resistance). We have analyzed the androgen receptor gene of one patient (P321) with receptor-positive, complete testicular feminization and detected a single nucleotide substitution at nucleotide 2006 (G -> C) within the second "zinc finger" of the DNA-binding domain that results in the conversion of the arginine residue at position 615 into a proline residue. Introduction of this mutation into the androgen receptor cDNA and transfection of the expression plasmid into eukaryotic cells lead to the synthesis of a receptor protein that displays normal binding kinetics but is inactive in functional assays of receptor activity. We conclude that substitution mutations in the DNA-binding domain of the androgen receptor are one cause of "receptor-positive" androgen resistance.

Introduction

Androgen Insensitivity Syndrome (AIS) presents a fascinating clinical paradox: individuals with a 46,XY karyotype and normal male levels of circulating androgens develop as phenotypic females. Historically, most cases were attributed to "receptor-negative" resistance, where the androgen receptor (AR) was either absent or unable to bind its ligand. However, a subset of patients—approximately 10%—exhibit "receptor-positive" resistance. In these cases, the AR is expressed at normal levels and binds hormone with normal affinity, yet the physiological response is absent. This study investigates the molecular basis of this phenomenon in patient P321.

Mapping the Mutation

Through genomic analysis, researchers identified a single nucleotide substitution (G to C at position 2006) in the AR gene of patient P321. This point mutation results in the replacement of an arginine residue with a proline at position 615.

Schematic of the androgen receptor protein in patient P321 compared to a normal receptor, highlighting the Arg(615) to Pro mutation in the DNA-binding domain.

Structural and Functional Impact

The mutation occurs within the second "zinc finger" of the DNA-binding domain (DBD). Zinc fingers are critical structural motifs that allow the receptor to recognize and bind specific DNA sequences known as androgen response elements. Arginine 615 is a highly conserved residue within this domain. The substitution of proline is particularly disruptive; proline is a known "helix breaker" due to its rigid cyclic structure, which prevents the formation of the alpha-helical backbone necessary for proper DNA interaction.

Experimental Validation

To confirm that this single amino acid change was responsible for the clinical phenotype, the researchers utilized site-directed mutagenesis to introduce the P321 mutation into a normal AR cDNA. When transfected into eukaryotic cells, the mutant receptor expressed normally and bound dihydrotestosterone (DHT) with an affinity ($K_d$ ~0.5 nM) comparable to the wild-type receptor ($K_d$ ~0.8 nM).

However, functional assays using a reporter gene (MMTV-CAT) revealed that the mutant receptor was virtually inactive. As shown in the CAT assay results, the mutant receptor retained only about 2% of the transcriptional activity of the normal receptor, explaining the complete androgen resistance observed in the patient.

Functional assay comparing transcriptional activity of normal and mutant androgen receptors.

Conclusion

This landmark study demonstrated the modular nature of nuclear receptors. By identifying a mutation that selectively abolishes DNA binding while leaving ligand binding intact, the authors provided clear evidence that these two functions are mediated by distinct protein domains. This finding established a new paradigm for understanding "receptor-positive" androgen resistance, shifting the focus from hormone binding to the downstream mechanics of gene regulation.

Summary updated

Abstract

Androgen resistance is associated with a wide range of quantitative and qualitative defects in the androgen receptor. However, fibroblast cultures from approximately 10% of patients with the clinical, endocrine, and genetic features characteristic of androgen resistance express normal quantities of apparently normal androgen receptor in cultured genital skin fibroblasts (receptor-positive androgen resistance). We have analyzed the androgen receptor gene of one patient (P321) with receptor-positive, complete testicular feminization and detected a single nucleotide substitution at nucleotide 2006 (G----C) within the second "zinc finger" of the DNA-binding domain that results in the conversion of the arginine residue at position 615 into a proline residue. Introduction of this mutation into the androgen receptor cDNA and transfection of the expression plasmid into eukaryotic cells lead to the synthesis of a receptor protein that displays normal binding kinetics but is inactive in functional assays of receptor activity. We conclude that substitution mutations in the DNA-binding domain of the androgen receptor are one cause of "receptor-positive" androgen resistance.
BibTeX
@article{marcelli1991mutation,
  author = {Marco Marcelli and S. Zoppi and Placido B. Grino and Jim E. Griffin and Jean D. Wilson and Michael J. McPhaul},
  title = {{A mutation in the DNA-binding domain of the androgen receptor gene causes complete testicular feminization in a patient with receptor-positive androgen resistance.}},
  journal = {Journal of Clinical Investigation},
  year = {1991},
  doi = {10.1172/jci115076},
}
Figure